Phase II Study of <sup>177</sup> Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers
<sup>177</sup>Lu-DOTATATE demonstrated effectiveness and acceptable safety profile for progressive, metastatic PPGL. CRS may occur but can be mitigated through pretreatment with antihypertensives, and, when appropriate, intensified monitoring in the ICU with intravenous antihypertensives.
Authors
- Sara Talvacchio (ORCID: https://orcid.org/0009-0006-6969-4735)
- Erich P. Huang (ORCID: https://orcid.org/0000-0002-8458-655X)
- Corina Millo
- Barış Türkbey (ORCID: https://orcid.org/0000-0003-0853-6494)
- Inna Shamis
- Jaydira Del Rivero (ORCID: https://orcid.org/0000-0001-9710-4030)
- Joanna Kłubo-Gwieździńska (ORCID: https://orcid.org/0000-0001-8633-4420)
- Joanna H. Shih (ORCID: https://orcid.org/0000-0001-9815-3651)
- Jorge A. Carrasquillo (ORCID: https://orcid.org/0000-0002-8513-5734)
- Esther Mena (ORCID: https://orcid.org/0000-0003-0015-0597)
- Karel Pacák (ORCID: https://orcid.org/0000-0002-3541-3767)
- Frank I. Lin (ORCID: https://orcid.org/0000-0003-3539-1454)
- Freddy E. Escorcia (ORCID: https://orcid.org/0000-0002-0727-3242)
- Liza Lindenberg (ORCID: https://orcid.org/0000-0002-8514-0648)
- Abhishek Jha (ORCID: https://orcid.org/0000-0002-1489-2471)
- Peter Herscovitch
- Clara Chen
- Joy Zou
- Yating Teng (ORCID: https://orcid.org/0000-0001-6568-9783)
- Peter L. Choyke
Institutions
- National Institutes of Health (US)
- Uniformed Services University of the Health Sciences (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Office of the Director (US)
- National Cancer Institute (UA)
- Institute of Endocrinology (CZ)
- National Cancer Institute (US)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1200/jco-25-00791
- Citations
- 4
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 8.03